EMVision Medical Devices (EMV) H1 2026 earnings summary

Executive summary

• Developed portable neurodiagnostic devices for acute neurological emergencies, targeting stroke and traumatic brain injury markets with multi-billion-dollar potential and unmet needs in acute care and rural health.

• Over $60 million invested in R&D, with strong clinical data, global partnerships, and significant grant agreements, including a $3M CRC-P grant for regional stroke care studies.

• Six pivotal clinical studies underway, including collaborations with leading stroke centers, ambulance services, and regional partners.

• Strong balance sheet with $17.5 million cash, $7.0 million in secured grants, and $3.8 million R&D rebate expected.

• Loss after tax for the half-year was $3,967,663, up from $3,571,869 year-over-year, mainly due to higher non-cash share-based payment expenses.

Financial highlights

• Net loss after tax for 1H26 was $3.97 million, compared to $3.57 million loss in 1H25, with net loss per share at 4.45 cents.

• Total non-dilutive grant income and R&D tax incentive income reached $3.8 million for the half.

• Cash and cash equivalents at period end were $17,545,236, up from $10,456,814 at June 2025, following a $14 million capital raise.

• Total expenses rose to $8,014,381 (from $6,883,300), driven by R&D, employee, and share-based payment costs.

• Net assets increased to $19,741,470 from $9,282,964 at June 2025.

Outlook and guidance

• Targeted completion of pivotal trial enrolment and readout in 1H26, with FDA De Novo submission planned.

• Multiple clinical studies progressing, including aeromedical, mobile stroke unit, and road ambulance studies.

• Anticipates further grant receipts contingent on milestone achievements, including $4M from the Industry Growth Program and $2.6M from CRC-P through 2028.

• Expects to receive a $3.8M R&D Tax Incentive rebate in Q1 2026.

• Commercial launch focused on the US 'Stroke Belt' region, with plans for national and international expansion.